Guard Therapeutics International AB (publ) (STO:GUARD)

Sweden flag Sweden · Delayed Price · Currency is SEK
1.600
+0.025 (1.59%)
At close: Mar 6, 2026
-92.00%
Market Cap 32.27M
Revenue (ttm) n/a
Net Income (ttm) -108.85M
Shares Out 20.17M
EPS (ttm) -6.04
PE Ratio n/a
Forward PE 0.70
Dividend n/a
Ex-Dividend Date n/a
Volume 3,359
Average Volume 23,055
Open 1.555
Previous Close 1.575
Day's Range 1.555 - 1.625
52-Week Range 1.100 - 27.000
Beta -0.24
RSI 42.76
Earnings Date Feb 20, 2026

About STO:GUARD

Guard Therapeutics International AB (publ), a clinical-stage biotechnology company, identifies and develops medicines to treat kidney diseases in Sweden. Its pipeline products include RMC-035, an intact therapeutic A1M protein, that is in Phase 2b clinical trial for kidney protection with open-heart surgery; in Phase 2a clinical trial for kidney transplantation; and is in preclinical trial to treat Sepsis. It also develops GTZ peptides, a modified A1M-derived peptides which is in preclinical studies for the treatment of CKD and diabetes, heart ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2008
Employees 12
Stock Exchange Nasdaq Stockholm
Ticker Symbol GUARD
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.